Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTWUXR)

• Drug Name: Chlormezanone Drug Info
• Synonyms: Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide
• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 2717
  ChEBI ID: CHEMBL3619
  CAS Number: CAS 80-77-3
  TTD Drug ID: D0S1OE
  INTEDE Drug ID: DR2270

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Regulation of lipolysis in adipocytes	2.19	0.00e+0	52/55 (94.55%)	PTGER3;PIK3CD;PLIN1;...
Ribosome biogenesis in eukaryotes	1.98	3.55e-3	52/108 (48.15%)	GNL3;RAN;NAT10;...
Mitophagy	-1.62	4.88e-2	56/68 (82.35%)	MFN2;CALCOCO2;BNIP3L;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.63	4.87e-2	79/89 (88.76%)	PIK3R3;PTPN11;CD247;...
Inflammatory bowel disease	-1.64	4.43e-2	58/65 (89.23%)	SMAD2;IL18RAP;RORA;...
Graft-versus-host disease	-1.66	3.79e-2	32/42 (76.19%)	HLA-DPB1;KIR2DL3;HLA-B;...
Lysosome	-1.67	3.48e-2	115/128 (89.84%)	CTSO;DNASE2B;GM2A;...
Phagosome	-1.72	2.18e-2	118/152 (77.63%)	THBS3;FCGR2A;HLA-C;...
Antigen processing and presentation	-1.72	2.23e-2	60/78 (76.92%)	HLA-DPB1;KIR2DL4;KIR2DL3;...
Pertussis	-1.73	2.28e-2	64/76 (84.21%)	IRAK4;JUN;TLR4;...
Legionellosis	-1.73	2.40e-2	51/57 (89.47%)	HSPA1A;TLR4;NAIP;...
NF-kappa B signaling pathway	-1.73	2.46e-2	90/104 (86.54%)	BCL2L1;IRAK4;IL1R1;...
Rheumatoid arthritis	-1.74	2.17e-2	78/93 (83.87%)	TCIRG1;CTSK;HLA-DMB;...
Necroptosis	-1.74	2.31e-2	113/159 (71.07%)	IRF9;CAMK2G;SPATA2;...
Tuberculosis	-1.76	2.30e-2	159/180 (88.33%)	FCGR2A;MAPK10;CARD9;...
Phenylalanine metabolism	-1.77	2.20e-2	14/17 (82.35%)	MIF;MAOA;HPD;...
Metabolism of xenobiotics by cytochrome P450	-1.78	2.18e-2	49/77 (63.64%)	ADH1C;CYP1A1;SULT2A1;...
Leishmaniasis	-1.79	2.05e-2	67/77 (87.01%)	FCGR2A;PTPN6;IFNGR1;...
Tryptophan metabolism	-1.81	1.68e-2	35/42 (83.33%)	MAOA;TDO2;CYP1A1;...
Lipid and atherosclerosis	-1.83	1.72e-2	190/215 (88.37%)	BCL2;MMP9;CYP1A1;...
Fluid shear stress and atherosclerosis	-1.83	1.91e-2	123/139 (88.49%)	BMPR1B;SUMO1;BCL2;...
Neutrophil extracellular trap formation	-1.87	1.08e-2	101/189 (53.44%)	SLC25A6;PADI4;VWF;...
Bladder cancer	-1.89	7.03e-3	40/41 (97.56%)	HBEGF;CDH1;RPS6KA5;...
Arginine and proline metabolism	-1.91	4.10e-3	39/50 (78%)	PRODH2;CKM;ODC1;...
Glutathione metabolism	-1.92	4.92e-3	43/57 (75.44%)	G6PD;GCLC;GSTM5;...
Th1 and Th2 cell differentiation	-1.95	3.08e-3	80/92 (86.96%)	MAPK10;CD3G;IFNGR1;...
Histidine metabolism	-2.06	0.00e+0	16/22 (72.73%)	ASPA;MAOA;CNDP2;...
Staphylococcus aureus infection	-2.14	0.00e+0	72/95 (75.79%)	FCGR2A;C1R;C3AR1;...
Complement and coagulation cascades	-2.28	0.00e+0	76/85 (89.41%)	C8B;KNG1;F2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼